Accelerating discovery of functional mutant alleles in cancer

Cancer Discovery

Volumn 8, Issue 2, 2018, Pages 174-183

  Chang, Matthew T ^a,b,d   Bhattarai, Tripti Shrestha ^a   Schram, Alison M ^a   Bielski, Craig M ^a   Donoghue, Mark T A ^a   Jonsson, Philip ^a   Chakravarty, Debyani ^a   Phillips, Sarah ^a   Kandoth, Cyriac ^a   Penson, Alexander ^a   Gorelick, Alexander ^a   Shamu, Tambudzai ^a   Patel, Swati ^a   Harris, Christopher ^a   Gao, JianJiong ^a   Sumer, Selcuk Onur ^a   Kundra, Ritika ^a   Razavi, Pedram ^a   Li, Bob T ^a   Reales, Dalicia N ^a   Socci, Nicholas D ^a   Jayakumaran, Gowtham ^a   Zehir, Ahmet ^a   Benayed, Ryma ^a   Arcila, Maria E ^a   Chandarlapaty, Sarat ^a   Ladanyi, Marc ^a   Schultz, Nikolaus ^a   Baselga, José ^a   Berger, Michael F ^a   Rosen, Neal ^a   Solit, David B ^a,c   Hyman, David M ^a   Taylor, Barry S ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NERATINIB; TUMOR MARKER;

ARTICLE; BREAST CANCER; COMPUTER MODEL; FRAMESHIFT MUTATION; GALLBLADDER CANCER; GENE MUTATION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; HUMAN; MALIGNANT NEOPLASM; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; ONCOGENE; POLYACRYLAMIDE GEL ELECTROPHORESIS; RETROSPECTIVE STUDY; RISK FACTOR; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE; WESTERN BLOTTING; ALLELE; CODON; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; INDEL MUTATION; MUTATION; NEOPLASM; PROCEDURES;

ALLELES; BIOMARKERS, TUMOR; CODON; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDEL MUTATION; MUTATION; NEOPLASMS;

EID: 85041401939     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-17-0321     Document Type: Article

References (32)

1. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 2015; 17: 251-64.
2. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023-31.
3. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3: 111ra21.
4. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin- fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014; 20: 682-8.
5. Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013; 153: 17-37.
6. Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med 2016; 8: 109.
7. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015; 373: 726-36.
8. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017; 23: 703-13.
9. Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 2014; 24: 52-60.
10. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 2016; 34: 155-63.
11. Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet 2016; 48: 675-80.
12. Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010; 70: 10038-43.
13. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 2000; 19: 3078-85.
14. Berger AH, Brooks AN, Wu X, Shrestha Y, Chouinard C, Piccioni F, et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell 2016; 30: 214-28.
15. Kim E, Ilic N, Shrestha Y, Zou L, Kamburov A, Zhu C, et al. Systematic functional interrogation of rare cancer variants identifies oncogenic alleles. Cancer Discov 2016; 6: 714-26.
16. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
17. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
18. Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Anh TN, Cin H, et al. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 2011; 129: 2297-303.
19. Foster SA, Whalen DM, Ozen A, Wongchenko MJ, Yin J, Yen I, et al. Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2. Cancer Cell 2016; 29: 477-93.
20. Hyman DM, Smyth L, Bedard PL, Oza AM, Dean E, Armstrong A, et al. AZD5363, a catalytical pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solit tumors. Mol Cancer Ther 2015; Abstract B109.
21. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligandbinding domain mutations in hormone-resistant breast cancer. Nat Genet 2013; 45: 1439-45.
22. Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005; 105: 4792-9.
23. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-21.
24. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol 2017; 2017.
25. Hyman DM, Piha-Paul SA, Rodon J, Saura C, Shapiro GI, Quinn DI, et al. Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 basket study. Cancer Res 2017; 77: CT001-CT.
26. Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, et al. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I doseescalation and expansion study. Cancer Discov 2018; 8: 184-95.
27. Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a shared vision for cancer genomic data. N Engl J Med 2016; 375: 1109-12.
28. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-4.
29. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
30. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016; 536: 285-91.
31. Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res 2016; 44: D862-8.
32. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161: 1215-28.